Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25844821 | 1.00 | PIK3CD (0.37) | PIK3CDEGFRERBB2FGFR2CHRNB2 | |
| SCHEMBL2842621 | 0.84 | PIK3CD (0.38) | PIK3CDEGFRERBB2FGFR2 | |
| SCHEMBL14165483 | 0.84 | PIK3CD (0.38) | PIK3CDEGFRERBB2FGFR2 | |
| SCHEMBL14165482 | 0.84 | PIK3CD (0.38) | PIK3CDEGFRERBB2FGFR2 | |
| SCHEMBL2842616 | 0.84 | PIK3CD (0.38) | PIK3CDEGFRERBB2FGFR2 | |
| SCHEMBL23936998 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL15709158 | 0.82 | PIK3CD (0.37) | PIK3CDEGFRERBB2FGFR2 | |
| SCHEMBL14617834 | 0.82 | HCAR2 (0.41) | PIK3CDEGFRERBB2FGFR2 | |
| Hydrochloric Acid SCHEMBL15709160 | 0.82 | PIK3CD (0.37) | PIK3CDEGFRERBB2FGFR2 | |
| SCHEMBL2227392 | 0.82 | PIK3CD (0.37) | PIK3CDEGFRERBB2FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | claimed |
| US-20240277722-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | AURIGENE ONCOLOGY LTD (IN) | 2024-08-22 | — | — | US | claimed |
| US-20240016811-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-MICROTUBULE AGENT | AURIGENE ONCOLOGY LIMITED (IN) | 2024-01-18 | — | — | US | claimed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | claimed |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-31 | — | — | US | claimed |
| EP-3222620-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2019-11-20 | — | — | EP | claimed |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | disclosed |
| US-20240277722-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | AURIGENE ONCOLOGY LTD (IN) | 2024-08-22 | — | — | US | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | PIK3CD 695/4885EGFR 2065/4885ERBB2 1170/4885 |
| US-20240277722-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | CDK7, CDK17, CDK6 | PIK3CD 704/4885EGFR 1287/4885ERBB2 1645/4885 |
| US-20240016811-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-MICROTUBULE AGENT | CDK7, CDK17, HDAC7 | PIK3CD 1049/4885EGFR 2251/4885ERBB2 2137/4885 |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | PIK3CD 695/4885EGFR 2065/4885ERBB2 1170/4885 |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | PIK3CD 695/4885EGFR 2065/4885ERBB2 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.